Genmab announced positive Phase 2 and Phase 1b/2 trial results for epcoritamab, a T-cell engaging antibody, in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are ineligible for standard chemotherapy. The Phase 2 trial showed a 67% overall response rate with epcoritamab monotherapy, while the Phase 1b/2 trial combining epcoritamab with R-mini-CHOP chemotherapy showed a 93% response rate. These treatments demonstrated durable remissions, high minimal residual disease negativity, and manageable safety profiles, offering promising new options for elderly patients with limited treatment choices. The data were presented at the 2026 European Hematology Association Congress and support further development of epcoritamab in this patient population.
The US and Iran are expected to finalize a peace agreement within 24 hours, potentially ending over three months of conflict that disrupted global energy supplies and raised gasoline prices. Pakistan's Prime Minister Shehbaz Sharif announced preparat...
SpaceX went public with a valuation close to $2 trillion, marking a significant milestone for the company. Investor Shaun Maguire praised Elon Musk as a visionary entrepreneur and highlighted SpaceX's potential for dramatic growth, driven by projects...
A coalition of state attorneys general has launched an investigation into OpenAI, issuing a subpoena from New York demanding documents on advertising, user engagement, data handling, and protections for minors and seniors. OpenAI is cooperating and e...
Bitcoin mining difficulty fell by 9.55%, the second-largest drop in 2025, due to a decline in network hashrate from nearly 1 ZH/s to about 861 EH/s in early June. This reduction lowers the work needed to mine blocks, increasing bitcoin output per act...
The Ethereum Foundation's Kohaku project introduces an opt-in upgrade allowing users to quantum-proof their wallets for about $0.07 each, using the ERC-4337 smart account standard. This upgrade avoids the need for a network-wide hard fork by letting ...
